Kymera Therapeutics

Inventing New Possibilities, Transforming Treatment Paradigms

Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.

Vision
Reinvent the treatment of human disease
Mission
Build a global medicines company that harnesses novel modalities to revolutionize healthcare

The Kymera Team

Management Team
Board Of Directors
Scientific Advisory Board
Academic Collaborators
Partners
Investors
Management Team
Management Team
Board Of Directors
Scientific Advisory Board
Academic Collaborators
Partners
Investors
Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer
Read Bio
Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer

Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has built a pipeline of multiple clinical stage, first-in-class degrader medicines; developed a best-in-class drug discovery platform; raised more than $1 billion of capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines. Before founding Kymera, Nello was an Entrepreneur in Residence at Atlas Venture and previously led discovery research at Raze Therapeutics, a cancer metabolism startup. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 80 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.

Jeremy Chadwick, PhD
Chief Operating Officer
Read Bio
Jeremy Chadwick, PhD
Chief Operating Officer

Prior to Kymera, Dr. Chadwick served as Senior Vice President, Head of Global Development Office at Takeda Pharmaceuticals. During his time there, his responsibilities included Head of Global Regulatory Affairs, as well as managing Global Drug Safety, Global Clinical Supply Chain and several groups supporting Global Development Operations. Before Takeda, Dr. Chadwick was Group Vice President and Head of Clinical Development Operations at Shire Pharmaceuticals. Earlier in his career, Dr. Chadwick held a number of senior development roles with broad responsibilities including program management, development operations, regulatory affairs, biostatistics and data management at The Medicines Company, Synta Pharmaceuticals, Vertex Pharmaceuticals and Glaxo Group Research. Dr. Chadwick has been involved in several successful global approvals spanning decades across multiple therapeutic areas. Dr. Chadwick previously served as chairman of the Board of Directors at Accumulus Synergy, a global organization developing a transformative data exchange platform designed to enhance how biopharmaceutical innovators and regulators bring safe and effective medicines to patients faster. He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the UK.

Ellen Chiniara, JD
Chief Legal Officer and Corporate Secretary
Read Bio
Ellen Chiniara, JD
Chief Legal Officer and Corporate Secretary

Prior to Kymera, Ellen served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Alexion Pharmaceuticals, where she was responsible for all legal, intellectual property and governance matters, and was the executive sponsor of the Corporate Social Responsibility program, until the company’s acquisition by AstraZeneca in 2021. In this role, she built and transformed the legal function, mission, and culture at the company by focusing on solutions, developing and mentoring talent, and implementing new technology and infrastructure. Before Alexion, Ellen was General Counsel at Alere, Inc., a point-of-care diagnostics company, where she spent over a decade managing various legal, government affairs, and governance functions through rapid growth and significant acquisitions globally. Earlier in her career, she was responsible for the legal function of the US neurology division at Serono and was a Partner at the law firm Hale and Dorr LLP.

Ellen currently serves as a member of the Board of Directors at Compass Therapeutics. She graduated magna cum laude from Bryn Mawr College and earned her Juris Doctor from Stanford University School of Law.

Jared Gollob, MD
Chief Medical Officer
Read Bio
Jared Gollob, MD
Chief Medical Officer

In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTROTM for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

Bruce Jacobs, CFA, MBA
Chief Financial Officer
Read Bio
Bruce Jacobs, CFA, MBA
Chief Financial Officer

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston and serves on the Board of Advisors for Life Science Cares.

Karen Weisbach
Vice President, People and Culture
Read Bio
Karen Weisbach
Vice President, People and Culture

As Vice President, People and Culture, Karen brings more than 15 years of experience in human resources and operations, designing values-based initiatives to enhance company culture, improve employee experience and manage change in dynamic, innovative organizations in the biopharmaceutical industry. Prior to Kymera, she served in human resource leadership roles at bluebird bio, Inc., including building and leading the global People Partner function responsible for driving talent and organizational strategies with an emphasis on employee engagement, development, and performance.

Juliet Williams, PhD
Senior Vice President, Head of Research
Read Bio
Juliet Williams, PhD
Senior Vice President, Head of Research

As Senior Vice President, Head of Research at Kymera Therapeutics, Juliet brings more than 20 years of drug development experience, including service at Novartis, Sanofi, Millennium, and Curis. Prior to Kymera, Juliet was the Head of Oncology Biology and Small Molecule Drug Discovery at Novartis Institutes for Biomedical Research and served as the Head of Oncology Pharmacology at both Novartis and Sanofi. Juliet holds a degree in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Developmental Biology from University College London. Juliet subsequently completed a Wellcome Postdoctoral Fellowship at University College London in Developmental Biology.

Brian Albarran, PhD, MBA
Senior Vice President, Corporate Strategy
Read Bio
Brian Albarran, PhD, MBA
Senior Vice President, Corporate Strategy

As Senior Vice President, Head of Corporate Strategy at Kymera Therapeutics, Brian is responsible for the development and coordination of strategic initiatives that drive value creation and corporate growth. Brian joined Kymera from TESARO (now a GSK Company) where, as a Program Team Leader, he oversaw the FDA approval of the NK1RA rolapitant/Varubi IV and led multiple clinical programs in immuno-oncology, including the anti-PD-1 dostarlimab/Jemperli. While at TESARO, Brian also built and led the Competitive Intelligence function to support both clinical and commercial oncology programs, including the PARP inhibitor niraparib/Zejula. Brian was previously a strategy consultant at Leerink and Navigant Consulting after numerous biotech roles in process development, manufacturing, and business development at ICOS, Trubion Pharmaceuticals, and Emergent BioSolutions. Brian earned his MBA from the Wharton School of Business and holds a PhD in Bioengineering from the University of Washington and a BSE in Biomedical Engineering from Duke University.

Todd Cooper
Senior Vice President, Corporate Affairs
Read Bio
Todd Cooper
Senior Vice President, Corporate Affairs

As Senior Vice President, Corporate Affairs, Todd’s career has focused on developing and implementing integrated communications, advocacy and engagement strategies for life science companies. Before joining Kymera, Todd was Global Head of Science Communications at Sanofi, where he was responsible for strengthening the company’s scientific reputation, highlighting its pipeline and enhancing the culture of the R&D organization. Prior to Sanofi, Todd was Global Head of Brand and Science Communications at Biogen, where he led internal and external communications supporting Biogen’s marketed products, pipeline programs and R&D organization. At Biogen, he oversaw six product approvals, and generated awareness of the company’s academic, patient advocacy and industry collaborations and partnerships. Todd graduated from the University of Rochester with a B.A. in English.

Kevin Dushney
Senior Vice President, IT and Operations
Read Bio
Kevin Dushney
Senior Vice President, IT and Operations

As Vice President of Information Technology at Kymera Therapeutics, Kevin brings over 20 years of experience in information technology (IT) in the biopharmaceutical industry.  Kevin has extensive experience in planning, designing, and implementing innovative IT strategies and solutions to support growth across preclinical to commercial-stage organizations. Kevin previously held IT and operations leadership roles at Editas Medicine, Inc., Synageva Biopharma Corp., Zafgen, Inc., and Alnylam Pharmaceuticals. Kevin holds a Bachelor’s degree from the University of Massachusetts Amherst.

Ashwin Gollerkeri, MD
Senior Vice President, Head of Development
Read Bio
Ashwin Gollerkeri, MD
Senior Vice President, Head of Development

As Senior Vice President, Head of Development at Kymera Therapeutics, Ashwin is responsible for all phases of Kymera’s drug development programs.  Ashwin brings more than 20 years of drug development experience, including service at Pfizer Inc., Array BioPharma, Novartis AG, and Bristol-Myers Squibb Company (BMS). As Vice President of Clinical Science-Oncology at Array, Ashwin’s efforts led to successful filings of New Drug Applications for the targeted cancer therapies BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib). Ashwn has also held various leadership roles in clinical development and research at Pfizer, Novartis, and BMS. Ashwin holds a BA degree in Cell and Developmental Biology from Northwestern University and an MD from the University of Kansas School of Medicine. Ashwin subsequently trained in Internal Medicine and completed a Chief Residency at The Miriam Hospital-Brown University School of Medicine and in Medical Oncology at Yale University School of Medicine.

Rebecca Mosher, MD
Senior Vice President, Translational Medicine
Read Bio
Rebecca Mosher, MD
Senior Vice President, Translational Medicine

As SVP, Translational Medicine, Beccy joined Kymera to provide strategic oversight and tactical support for translational activities across all clinical stage and discovery programs. She has worked in the industry setting for more than 20 years. Prior to joining Kymera, she was Vice President of Translational Medicine at Mersana Therapeutics. She previously held positions of increasing responsibility in translational research and molecular pathology at Novartis, Vertex, and Millennium. Beccy graduated from Harvard College and received her MD from Columbia University. Her residency and fellowship training were in Anatomic and Clinical Pathology, and Cytopathology at Brigham and Women’s Hospital and Boston Medical Center. Before joining industry, Beccy practiced as a pathologist in the Boston area.

Vijay Sabesan
Senior Vice President, Technical Operations
Read Bio
Vijay Sabesan
Senior Vice President, Technical Operations

As Senior Vice President, Technical Operations, Vijay brings over 25 years of experience in the pharmaceutical and biotech industry, including over 10 years in senior leadership roles. Prior to joining Kymera, Vijay was Senior Vice President, Technical Operations at Theravance Biopharma where he was responsible for leading the process R&D, pharmaceutical development, analytical development, supply chain management and CMC project management functions. Vijay has extensive experience in drug development, regulatory interactions, and manufacturing. At Theravance, he led CMC efforts towards commercial approval of VIBATIV® and YUPELRI®, and partnership deals with several large pharma companies. Vijay holds a Bachelor’s Degree from the Indian Institute of Technology Madras, and a Master of Science from Rutgers, The State University of New Jersey, both in Chemical Engineering.

Jolly Bhatia
Vice President, Quality
Read Bio
Jolly Bhatia
Vice President, Quality

As Vice president, Quality, Jolly brings 25 years in quality oversight of manufacturing and clinical trial lifecycle activities including process and product development, clinical and commercial supply chains and new product launch. Prior to Kymera, he served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation. He holds a Bachelor of Pharmacy degree from Birla Institute of Technology and Science and a Master’s degree in Industrial Pharmacy from St. John’s University.

Melissa Brody
Vice President, Business Development
Read Bio
Melissa Brody
Vice President, Business Development

As Vice President, Business Development, Melissa brings nearly a decade of experience in the biotechnology industry advising biopharma companies on strategic transactions. Prior to Kymera, Melissa was a Principal at Aquilo Partners, a boutique life sciences investment bank, where she was responsible for leading the execution of collaborations, licensing transactions, private placements, and mergers and acquisitions across a variety of therapeutic areas, including Kymera in its collaboration with Sanofi, Disarm in its sale to Lilly, and Protomer in its sale to Lilly. Melissa earned her Bachelor’s in Biology and Ecology (Phi Beta Kappa) from the University of Georgia, where she also played on the Georgia Bulldogs NCAA Division I Women’s Varsity Golf team.

Jeff Davis, MBA
Vice President, Head of Clinical Operations
Read Bio
Jeff Davis, MBA
Vice President, Head of Clinical Operations

As Vice President, Head of Clinical Operations at Kymera Therapeutics, Jeff is responsible for operational oversight and execution of all Kymera development programs. Jeff joined Kymera from FORMA Therapeutics where he performed a similar role of building out a development organization that scaled with the growing pipeline. Jeff has supported development programs focused in hematologic malignancies, blood and metabolic disorders. Prior to FORMA, Jeff helped oversee execution of the development programs and life cycle management for Iclusig® and Alunbrig® in CML and NSCLC, respectively. Jeff has also held similar positions at Biogen and Ziopharm Oncology. Jeff earned his MBA in Health Sector Management from Boston University and his BS in Biochemistry from Bates College.

Aimee Mishkin
Vice President, Regulatory Affairs
Read Bio
Aimee Mishkin
Vice President, Regulatory Affairs

As Head of Regulatory Affairs, Aimee is responsible for oversight and management of the Regulatory Affairs function at Kymera, including nonclinical, CMC and clinical regulatory strategies for all Kymera development candidates. Aimee has over 15 years of regulatory affairs experience in the biotechnology industry, serving as the lead regulatory strategist for several commercially successful medicines. Before joining Kymera, Aimee gained significant experience in small and midsized companies, with increasing levels of responsibility and leadership roles through her tenure at Forma Therapeutics, Clovis Oncology, Array BioPharma and OSI Pharmaceuticals. She has supported early and late-stage drug development programs in multiple therapeutic areas and has extensive experience in biotech-pharma co-development partnerships, regulatory intelligence research and due diligence, as well as clinical development plan execution. Aimee is a passionate patient advocate in her personal and professional lives with a focus on oncology patient engagement and advocacy and patient-focused drug development. She holds a B.S. in  Molecular, Cell and Developmental Biology and a B.A in English Literature from the University of Colorado, and an M.S. in Pharmacology and Toxicology from Michigan State University.

Aimee also serves as the Program Team Leader of Kymera’s IRAKiMID program, KT-413, currently under development for MYD88-mutant Diffuse large B-cell lymphoma, or DLBCL.

 

Anthony Slavin, PhD
Vice President, Immunology
Read Bio
Anthony Slavin, PhD
Vice President, Immunology

As Vice President, Immunology at Kymera Therapeutics, Anthony leads the Immunology team at Kymera Therapeutics and brings deep research and development experience in both small molecule and biologic drug discovery. He has been involved in multiple aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. for more than 20 years, leading discovery, and pharmacology teams, as well as being involved in efforts focused on the external identification and diligence of novel technologies and assets suitable for in-licensing and/or acquisition. Prior to joining Kymera, Anthony held leadership positions in Immunology at Abbvie and Boehringer Ingelheim, where he oversaw research departments dedicated to identifying and developing therapeutics for grievous autoimmune diseases, including the recently approved SKYRIZI, a monoclonal antibody targeting IL-23. He started his career at Tularik which was acquired by Amgen, and was a group leader at the Genomics Institute of the Novartis Research Foundation (GNF). Anthony holds a BSc (Hons.) and a PhD degree from the University of Melbourne and trained as a research fellow at Harvard Medical School and Stanford University.

Michael Todisco, MS
Vice President, Accounting & Finance
Read Bio
Michael Todisco, MS
Vice President, Accounting & Finance

As Vice President, Accounting & Finance at Kymera, Mike is responsible for all aspects of the company’s finance operations. Mike joined Kymera with over 25 years of experience, including 15 years in biotechnology. Mike was most recently Vice President Finance & Controller at Pear Therapeutics, and prior to that held Vice President positions at Karyopharm, Dicerna, BG Medicine and Dusa Pharmaceuticals. Earlier in his career, Mike spent time in public accounting with EY and KPMG in the audit practice. Mike obtained a BA in Economics from Colgate University and an MS in Accountancy from Northeastern University.

Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer
Read Bio
Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer

Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has built a pipeline of multiple clinical stage, first-in-class degrader medicines; developed a best-in-class drug discovery platform; raised more than $1 billion of capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines. Before founding Kymera, Nello was an Entrepreneur in Residence at Atlas Venture and previously led discovery research at Raze Therapeutics, a cancer metabolism startup. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 80 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.

Bruce Booth, DPhil
Chairman and Co-Founder
Read Bio
Bruce Booth, DPhil
Chairman and Co-Founder

Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Quench Bio. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics, miRagen (NASDAQ:MGEN), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), Unum Therapeutics (NASDAQ:UMRX), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, and the Gates Foundation. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer for Penn State, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.

Jeff Albers, JD, MBA
Read Bio
Jeff Albers, JD, MBA

Jeff Albers has more than 15 years of experience bringing important new medicines to patients with cancer and rare diseases in leadership roles in the biopharmaceutical industry. In 2014, he joined Blueprint Medicines as Chief Executive Officer and member of the board of directors and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including one FDA-approved therapy and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the Board of Advisors for Life Sciences Cares. He holds a BS from Indiana University and an MBA and JD from Georgetown University.

Pamela Esposito, PhD
Read Bio
Pamela Esposito, PhD

Pamela L. Esposito, PhD is currently the Chief Business Officer of Replimune (NASDAQ REPL). Since its inception, Pamela has been responsible for both corporate and business development, having raised over $400M. Over the past 18 years, Pamela has held a variety of strategy, commercial and business development positions in small biotech companies, playing lead roles in transformative deals for each company. Previously, she was Chief Business Officer at Ra Pharmaceuticals (NASDAQ RARX). As an early member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Early in her career, she was a director at Bioduro based in Beijing, China and Vion Pharmaceuticals in New Haven, CT. Currently, Pamela sits on the board of directors of Accent Therapeutics. Pamela earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.

Joanna Horobin, MB, ChB
Read Bio
Joanna Horobin, MB, ChB

Joanna Horobin, MB, ChB, is the former Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals.  Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer.  Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim).  Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®.

Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.

Gorjan Hrustanovic, PhD
Read Bio
Gorjan Hrustanovic, PhD

Dr. Gorjan Hrustanovic is Managing Director at BVF Partners L.P., where he focuses on biotech and therapeutic investments. Gorjan is currently serving on the board of Rain Therapeutics, Inc., Olema Pharmaceuticals, Inc, and is also a board observer at 4D Molecular Therapeutics.

Prior to joining BVF in 2015, Gorjan received his PhD in Cancer Biology & Cell Signaling at the University of California, San Francisco (UCSF), where he also co-founded a small biotech-focused investment fund. At UCSF, his research focus was personalized medicine and molecularly targeted therapy in non-small cell lung cancer. His research in cancer biology is published in peer-reviewed journals such as Nature Medicine, Oncogene, Cell Reports, and others. Gorjan earned his BS degree in Molecular Biology, and a BS in Economics/Management Science from UCSD.

John Maraganore, PhD
Read Bio
John Maraganore, PhD

Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization, including over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc., where he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy, and biotherapeutics functions. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, and an Executive Partner at RTW Investments. He is also Chair of the Board of Directors of Hemab Therapeutics and a member of the Board of Directors of Agios Pharmaceuticals, Beam Therapeutics and the Biotechnology Industry Organization, where he was Chair from 2017-2019. In addition, he serves on the Board of the Termeer Foundation – committed to continuing the legacy of the late Henri A. Termeer, as Chair of the n-Lorem Foundation Advisory Council – committed to meeting the needs of patients with nano-rare diseases, and as a strategic advisor to SalioGen, SQZ Biotechnologies, and other innovative companies.

Leigh Morgan
Read Bio
Leigh Morgan

Leigh Morgan is a senior executive with experience scaling profitable, high-performing organizations in the global biopharmaceutical, philanthropy, and public sectors. Ms. Morgan is currently Chief Strategy and Operating Officer for Nia Tero, a US-based non-profit working in solidarity with Indigenous peoples and movements worldwide. She is a key architect of the firm’s growth, inclusive of strategy, finance, innovation, communications, operations, impact investments and governance. Ms. Morgan also serves Vice-Chair/Chair-elect on the board of the Fred Hutch Cancer Center, is on the University of Washington Medical Center Advisory Board, and is an independent director at Curemark, a clinical-stage biotechnology company. Previously, she served as Chief Operating Officer of the Bill & Melinda Gates Foundation, where she oversaw a broad portfolio, including human resources, information technology and security, facilities and the foundation’s culture transformation efforts.  Prior to these positions, she held roles as Associate Chancellor at the University of California, San Francisco, Vice President and Global Head of Human Resources for Product Development at Genentech, and HR leadership roles at GSK. She holds a master’s degree in organization development from the American University and a bachelor’s degree from Duke University. She was awarded an honorary doctorate from the Asian University for Women in Bangladesh and is a member of the Council on Foreign Relations.

Victor Sandor, MDCM
Read Bio
Victor Sandor, MDCM

Victor Sandor, M.D.C.M., was most recently Chief Medical Officer at Array BioPharma, Inc. prior to its acquisition by Pfizer Inc. At Array, Victor was instrumental in obtaining the approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation, where he played a critical role in the approval of Jakafi® (ruxolitinib). Victor was also Vice President and Chief Medical Officer for Oncology at Biogen Idec and held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex® (anastrozole) for adjuvant use and the development of several early-stage programs through proof of concept. Victor serves on the Boards of Directors of Prelude Therapeutics, ADC Therapeutics, Istarti Oncology and Merus N.V. He received his M.D.C.M. from McGill University in Montreal, Canada, and completed Fellowship in Medical Oncology at the National Institutes of Health.

Elena Ridloff, CFA
Read Bio
Elena Ridloff, CFA

Elena Ridloff has over 20 years of experience in finance and the life sciences industry.  She is currently the Chief Financial Officer of a stealth biotechnology company.  Previously she was Executive Vice President and Chief Financial Officer for ACADIA Pharmaceuticals where she was responsible for leading corporate finance, accounting, investor relations and corporate affairs functions.  Prior to joining Acadia, Ms. Ridloff was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee. Additionally, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm serving the life sciences industry. She was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device, and life science sectors. She currently serves on the Board of Directors of Kronos Bio, Inc.

Ms. Ridloff received her BA in History and Sociology of Science from the University of Pennsylvania. She is also a CFA© charterholder.

Senior Director of Proteomics, Broad Institute
Professor, Rockefeller University and Investigator, Howard Hughes Medical Institute
Associate Professor, Oncology, Dana-Farber Cancer Institute
Chief Scientific Officer, Bicycle Therapeutics
American Cancer Society Professor and Director of the Center for Lymphoid Malignancies, Columbia University
Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute
Professor of General Pathology, Humanitas Clinical and Research Center
Professor of Chemistry, Yale University
Professor, Rheumatology, University of California San Diego
Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute